CompanyPrivateBoston, MA

Bambusa Therapeutics, Inc

SEC EDGAR ClinicalTrials.gov

SCHEDULE 13DNov 6Latest SEC filing

Form DFeb 26$53M sold

October 2026

Rapport closes $215.7 million stock offering and $172.5 million convertible notes sale

Oct 30Clinical readoutBambusa Therapeutics, Inc Decoy Therapeutics, IncUpdated

Bambusa Therapeutics files for IPO, discloses bispecific antibody data

Oct 9FinancingBambusa Therapeutics, Inc Decoy Therapeutics, Inc